BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils
Allergy2017Vol. 72(11), pp. 1666–1676
Citations Over TimeTop 11% of 2017 papers
Dubravka Smiljkovic, K. Blatt, Gabriele Stefanzl, Yulia Dorofeeva, Cathrin Skrabs, Margarete Focke‐Tejkl, Wolfgang R. Sperr, Ulrich Jaeger, Rudolf Valenta, Peter Valent
Abstract
BTK-targeting drugs are potent inhibitors of IgE-dependent histamine release in human basophils. The clinical value of BTK inhibition in the context of allergic diseases remains to be determined.
Related Papers
- → Targets for Ibrutinib Beyond B Cell Malignancies(2015)127 cited
- → Independent and Opposing Roles For Btk and Lyn in B and Myeloid Signaling Pathways(1998)73 cited
- → Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL(2019)3 cited
- → A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib(2021)2 cited
- → Abstract 3761: HSK26784: An oral PROTAC-BTK degrader for multiple B lymphocyte derived malignancies(2020)